ACAD
38.36
-0.54
-1.39%
AEMD
0.196
-0.01
-4.6341%
APRI
1.61
-0.13
-7.47%
ARNA
4.49
+0.05
+1.13%
ATEC
1.41
+0.01
+0.71%
CNAT
6.66
-0.15
-2.20%
CRXM
0.354
-0.007
-1.8056%
CYTX
0.985
+0.002
+0.183%
DXCM
69.43
-1.13
-1.60%
GNMK
10.69
-0.24
-2.20%
HALO
16.86
-0.08
-0.50%
ILMN
189.59
-3.01
-1.56%
INNV
0.145
-0.008
-4.918%
INO
10.35
-0.25
-2.36%
ISCO
0.074
+0.004
+5.714%
ISIS
66.37
-1.38
-2.03%
LGND
89.75
+0.83
+0.93%
LPTN
2.23
-0.01
-0.45%
MBVX
3.36
-0.01
-0.30%
MEIP
2.16
-0.02
-0.92%
MNOV
4.09
+0.11
+2.76%
MRTX
27.87
-0.15
-0.54%
MSTX
0.49
0.00
+1.03%
NBIX
43.37
-0.31
-0.71%
NUVA
43.99
+0.23
+0.53%
ONCS
0.268
-0.009
-3.423%
ONVO
5.19
+0.12
+2.37%
OREX
7.36
-0.08
-1.08%
OTIC
31.8
-1.32
-3.99%
QDEL
23.38
-0.43
-1.81%
RCPT
169.885
-1.255
-0.733%
RGLS
17.49
-0.8
-4.37%
RMD
65.7
-7.68
-10.47%
SCIE
0.026
+0.002
+7.9167%
SPHS
0.8
-0.025
-3.0542%
SRNE
10.52
-0.15
-1.41%
TROV
8.8
-0.13
-1.46%
VICL
1.005
-0.025
-2.427%
VOLC
17.99
0.00
0.00%
ZGNX
1.54
-0.11
-6.67%
ACAD
38.36
-0.54
-1.39%
AEMD
0.196
-0.01
-4.6341%
APRI
1.61
-0.13
-7.47%
ARNA
4.49
+0.05
+1.13%
ATEC
1.41
+0.01
+0.71%
CNAT
6.66
-0.15
-2.20%
CRXM
0.354
-0.007
-1.8056%
CYTX
0.985
+0.002
+0.183%
DXCM
69.43
-1.13
-1.60%
GNMK
10.69
-0.24
-2.20%
HALO
16.86
-0.08
-0.50%
ILMN
189.59
-3.01
-1.56%
INNV
0.145
-0.008
-4.918%
INO
10.35
-0.25
-2.36%
ISCO
0.074
+0.004
+5.714%
ISIS
66.37
-1.38
-2.03%
LGND
89.75
+0.83
+0.93%
LPTN
2.23
-0.01
-0.45%
MBVX
3.36
-0.01
-0.30%
MEIP
2.16
-0.02
-0.92%
MNOV
4.09
+0.11
+2.76%
MRTX
27.87
-0.15
-0.54%
MSTX
0.49
0.00
+1.03%
NBIX
43.37
-0.31
-0.71%
NUVA
43.99
+0.23
+0.53%
ONCS
0.268
-0.009
-3.423%
ONVO
5.19
+0.12
+2.37%
OREX
7.36
-0.08
-1.08%
OTIC
31.8
-1.32
-3.99%
QDEL
23.38
-0.43
-1.81%
RCPT
169.885
-1.255
-0.733%
RGLS
17.49
-0.8
-4.37%
RMD
65.7
-7.68
-10.47%
SCIE
0.026
+0.002
+7.9167%
SPHS
0.8
-0.025
-3.0542%
SRNE
10.52
-0.15
-1.41%
TROV
8.8
-0.13
-1.46%
VICL
1.005
-0.025
-2.427%
VOLC
17.99
0.00
0.00%
ZGNX
1.54
-0.11
-6.67%
Home » Archive by Category

Syndication

Quality Control Analyst — Chemistry (Sorrento Valley)

April 22, 2015 – 9:39 am

Summary: Responsible for QC chemical release testing of final products and intermediate bulk products. Perform analytical method evaluation, method validation, and Standard Operating Procedures generations/revisions. Help manage QC stability program […

Buyer/Planner, Biotech/Med Device experience required

April 22, 2015 – 8:52 am

Temporary Position
Procures and plans a variety of commodities including; biologicals, scientific equipment, contract services, and office/business supplies. Checks requisitions, obtains quotations, examines bid and makes awards. Coordinates procure […

Napa Summit 2015: Request Your Invite to Xconomy’s Most Elite Event

April 22, 2015 – 8:44 am

What are the forces shaping our innovation future—and who are the leaders who will build it? We can’t promise all the answers, but we can promise an unusually intimate and inspiring discussion…

[[Click headline to continue reading.]]

Napa Summit 2015: Request Your Invite to Xconomy’s Most Elite Event

April 22, 2015 – 8:44 am

What are the forces shaping our innovation future—and who are the leaders who will build it? We can’t promise all the answers, but we can promise an unusually intimate and inspiring discussion…

[[Click headline to continue reading.]]

Document Control Supervisor

April 22, 2015 – 8:29 am

Position Summary:
The Document Control Supervisor is responsible for the organization, maintenance, secure archiving and assist with establishing systems for controlling the generation and revision of all GXP documents. The Document Control Supervis […

Edico Genome Issued Broad Patent for DRAGENTM from United States Patent and Trademark Office

April 22, 2015 – 5:00 am

SAN DIEGO, April 22, 2015 /PRNewswire/ — Edico Genome, developer of the world’s first Bio-IT Processor, DRAGEN™, a solution that enables fast and cost-effective analysis of next-generation sequencing (NGS) data, today announced the United States Patent and Trademark Office has issued to the company U.S. patent number 9,014,989. This patent broadly covers proprietary processes that are core to DRAGEN, including bioinformatics protocols and functions necessary for the analysis of genomic data on integrated circuits and hardware processing platforms. The patent will provide protection until 2035 and is entitled “Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform.”

DRAGEN is a reconfigurable processor that is loaded with highly optimized algorithms for analysis of NGS data, including reference-based mapping, aligning, sorting, deduplication and variant calling. This approach has been shown to reduce analysis times from hours to minutes, while decreasing the need for clusters of large servers to process the data, which lowers costs related to storage space and IT infrastructure.

“This foundational patent, anticipated to be the first of many as Edico accumulates a sizeable patent portfolio, provides robust protection for our proprietary DRAGEN Bio-IT Processor,” said Pieter van Rooyen, Ph.D., Chief Executive Officer of Edico Genome. “Strong patent protection is also seen favorably by potential partners, and the issuance of this patent can further facilitate our ability to form partnerships such as our recently announced collaboration with Intel to develop solutions with their Xeon processors that accelerate NGS data analysis.”

About the DRAGEN Bio-IT Processor
DRAGEN™, the world’s first next-generation sequencing (NGS) Bio-IT processor, is a reconfigurable platform designed to massively accelerate secondary analysis of NGS while simultaneously improving accuracy, removing a key bottleneck in NGS workflow. DRAGEN is loaded with highly optimized algorithms for mapping, alignment, sorting and variant calling, and the flexible platform can be loaded with additional algorithms for a range of secondary analysis pipelines, such as whole genome or exome, RNAseq, methylome, microbiome and cancer. The solution can be integrated directly into NGS bioinformatics servers and sequencing instruments and is provided with accompanying software as a Platform-as-a-Service (PaaS). Interested parties may inquire about DRAGEN at http://www.edicogenome.com/dragen/get-dragen-now/.

About Edico Genome
Edico Genome, developer of the world’s first next-generation sequencing Bio-IT processor, DRAGEN™, is helping usher in the new era of precision medicine by enabling customized treatments and data-driven insights tailored to the individual. At the heart of personalized medicine is next-generation sequencing (NGS), which is growing at an unprecedented pace. By increasing the speed and accuracy of NGS data analysis, such as whole genome sequencing, Edico Genome’s computing platform makes it easier to discover links between DNA sequence variations and human disease, allowing clinicians and researchers to reveal answers more quickly. For more information, visit www.EdicoGenome.com and follow #DRAGENonFIRE.

Logo – http://photos.prnewswire.com/prnh/20140716/127788

 

SOURCE Edico Genome

WLSA Convergence Summit 2015 Highlights Changing Landscape of Improved, Faster and More Efficient Healthcare

April 22, 2015 – 5:00 am

Better, Cheaper Technology Services Address Needs of Significant Health Problems

SAN DIEGO, April 22, 2015 /PRNewswire/ — The Wireless Life Sciences Alliance’s annual flagship event, its 10th annual Convergence Summit devoted to speeding the adoption of innovative healthcare technologies, will be held May 26 – 28 at San Diego’s Omni Hotel.

The meeting gathers the most committed companies and leaders in connected health to highlight the use of digital health technologies and tech-enabled services that address the most important patient engagement and public health issues. Participants include representatives and CEOs of leading technology and healthcare companies, medical and government organizations and individuals who are the most committed to improving the health of people and transforming healthcare. 

“The technology, mobile and consumer product sectors have fully embraced the connected digital health sector,” said Rob McCray, co-founder, President and CEO of the Wireless Life Sciences Alliance.  “Policy makers, payors and consumers recognize the shortcomings in our current healthcare system, and the life sciences sector is embracing digital technologies. Attendees and speakers at this year’s Convergence Summit will share knowledge and insights on key issues, while all attendees of this exclusive meeting can build personal relationships that accelerate the creation, approval and adoption of better health solutions for institutions and consumers.”

Key topics on the Convergence Summit agenda include:

Creating Better Products.  Faster.  An exploration of the digital tools for accelerating the discovery, creation and integration of devices, drugs, applications and information into tech-enabled services for consumer and institutional channels. 

Critical Policy Issues.  This will be a deep dive into the steps that are being taken to address the principal regulatory and policy impediments to the adoption of connected health tools.   Special focus will be given to efforts currently underway and planned by the U.S. Department of Health and Human Services and their departments, the Food and Drug Administration and the Office of the National Coordinator for Health Information Technology along with the Federal Communications Commission and the Federal Trade Commission.

What Do Buyers Want?  Leading hospital systems and other customers are now embracing new business models and connected health tools.  Their leadership will describe what they need from the connected health community.

Voices of Patients and Consumers.  What do the end users want?  What are they buying?  What will cause them to share crucial information about their personal outcomes?

Keynoting the annual event will be Dr. Eric Topol, author of “The Patient Will See You Now” and “The Creative Destruction of Medicine” and Director of the Scripps Translational Science Institute (STSI). Topol is being joined by Google’s Brian Otis, Ph.D., Project Lead, for Google X focusing on the Smart Contact Lens

“The participation of Dr. Topol and Professor Otis demonstrates the level of interest and importance the Convergence Summit has conveyed to the cross section of industries the WLSA serves.

“For ten years the speakers and attendees of the Convergence Summit have described and created the near and long term future of healthcare,” added McCray. “Dr. Topol’s and Professor Otis’ insights on trend-setting topics range from the changing world of payments, treatments, patient diagnoses, hospitalization and more. They, along with other world class speakers, underscore the Summit’s significance.”

iAward Winners To Be Announced

In addition to the speakers and wide range of topics to be discussed, the 7th Annual TripleTree iAwards for Connected Health will recognize three best-in-class winners from a pool of nine Finalists and nearly 60 applicants. This year’s Finalists include Alegeus Technologies, ArborMetrix, Emmi Solutions, GoodRx, HealthPrize Technologies, Intelligent InSites, Magellan Health/Cobalt, Vital Connect and Welltok.  Past iAward Winners have included Airstrip, ShapeUp, Healthagen, and Homecare Homebase.

Nordic Connected Health Star Track Debuts

New to this year’s Convergence Summit is the “Nordic Connected Health Star Track,” a collaborative initiative to accelerate the success and international scaling of the best startups in the Nordic countries. Financed by the mobile industry and various Nordic government groups, the Connected Health Star Track features organizations and companies from Sweden, Norway, Finland, Iceland and Denmark that are traveling to the U.S. to highlight their region’s level of innovation with a unique “Nordic Connected Health Startrack Reception.” There, business advisors with entrepreneurial and regulatory expertise, rapid prototyping and other activities will share where collaborations can be made with U.S. companies to better compete in the global marketplace and to discover new business through the WLSA partnership.  Keynoting on behalf of the Nordic Connected Health initiative will be Bjorn Ekelund, Head of Device Technology and Ecosystem at Ericsson.

Registration and Additional Information

To register, or to obtain additional information about the Convergence Summit, visit the WLSA’s Convergence Summit web site or call WLSA’s San Diego office at 1-858-227-9409 between 9 a.m. and 5 p.m. PDT.

About Wireless-Life Sciences Alliance (WLSA)

The Wireless-Life Sciences Alliance (WLSA) is a special-purpose trade organization committed to accelerating the adoption of innovative technologies for personalized health and healthcare. Our community includes C-suite and senior-level executives, entrepreneurs, operating companies of all sizes, foundations, educational institutions, scientists, physicians, and policy makers. The WLSA is dedicated to creating value and improving health, globally, by stimulating the implementation of technologies that empower consumers and innovative institutions. WLSA partners and companies all over the world are using wireless and connected health innovations to better manage chronic conditions, pre-empt disease and improve the lives of the elderly and under-served populations.

Follow us on Twitter @WLSA_ORG  
Find us on Facebook 
Connect with us on LinkedIn 
Read our WLSA Blog 
View us on SlideShare 
Watch WLSA videos

Logo – http://photos.prnewswire.com/prnh/20120425/LA94378LOGO

 

SOURCE Wireless Life Sciences Alliance

Orexigen Announces Receipt of Paragraph IV Certification Notice

April 22, 2015 – 4:30 am

SAN DIEGO, April 22, 2015 /PRNewswire/ —  Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Orexigen and North American partner Takeda Pharmaceuticals have received notification of a Paragraph IV certification for certain patents for Contrave® (naltrexone HCl and bupropion HCl extended release) which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification resulted from the filing by Actavis Laboratories FL, Inc. of an Abbreviated New Drug Application (ANDA) challenging such patents for Contrave.

Orexigen and Takeda plan to vigorously enforce Contrave intellectual property rights.

In accordance with the Hatch-Waxman Act, Takeda and Orexigen have 45 days after effective notice of the Paragraph IV certification to file suit against the ANDA filer in order to obtain an automatic stay of FDA approval of the ANDA until the earlier of (i) 30 months from Takeda’s receipt of the notice or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed.

About Contrave
Contrave, approved by the United States Food and Drug Administration in September 2014, is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia).

The exact neurochemical effects of Contrave leading to weight loss are not fully understood. Contrave has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system).

Four 56-week multicenter, double-blind, placebo-controlled Phase 3 clinical trials were conducted to evaluate the effect of Contrave in conjunction with lifestyle modification in 4,536 subjects randomized to Contrave or placebo. In these studies, the most common adverse reactions (≥5 percent) seen in patients taking Contrave included nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.

The clinical trial program also includes a double-blind, placebo-controlled cardiovascular outcomes trial known as the Light Study. The primary objective of this study is to evaluate the occurrence of major adverse cardiovascular events (MACE) in overweight and obese adults with cardiovascular risk factors receiving Contrave. A second study, designed to address post-approval requirements in both Europe and the United States, is planned in order to further evaluate cardiovascular outcomes.

Important Safety Information
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS

SUICIDALITY AND ANTIDEPRESSANT DRUGS
CONTRAVE is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some other antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients.

NEUROPSYCHIATRIC REACTIONS IN PATIENTS TAKING BUPROPION FOR SMOKING CESSATION
Serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation. The majority of these reactions occurred during bupropion treatment, but some occurred in the context of discontinuing treatment. In many cases, a causal relationship to bupropion treatment is not certain, because depressed mood may be a symptom of nicotine withdrawal. However, some of the cases occurred in patients taking bupropion who continued to smoke. Although CONTRAVE is not approved for smoking cessation, observe all patients for neuropsychiatric reactions. Instruct the patient to contact a healthcare provider if such reactions occur.

Contraindications: CONTRAVE is contraindicated in patients with uncontrolled hypertension, seizure disorder, or current or prior diagnosis of anorexia nervosa or bulimia; in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs; with use of other bupropion-containing products; for use with chronic opioids or opiate agonists (eg, methadone) or partial agonists (eg, buprenorphine) or acute opiate withdrawal; during/within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with known allergy to any other component of CONTRAVE—anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported; in pregnancy.

Warnings and Precautions
Suicidal Behavior and Ideation: All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy or at times of dose changes, either increases or decreases. Consider changing the therapeutic regimen or discontinuing in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, or mania, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Alert families and caregivers of patients being treated with antidepressants about the need to monitor patients for the emergence of above mentioned symptoms, as well as the emergence of suicidality, daily and to report such symptoms immediately. Prescriptions for CONTRAVE should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment: CONTRAVE is not approved for smoking cessation treatment, but serious neuropsychiatric symptoms have been reported in patients taking bupropion for smoking cessation, including changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients for the occurrence of neuropsychiatric reactions. Instruct patients to contact a healthcare professional if such reactions occur.

Seizures: CONTRAVE can cause seizures. The risk of seizure is dose-related. Discontinue treatment and do not restart CONTRAVE in patients who experience a seizure. Use caution and consider the risk when prescribing CONTRAVE to patients with predisposing factors, clinical situations, and concomitant medications that may lower seizure threshold. Risk of seizure may be minimized by adhering to the recommended dosing schedule and avoiding co-administration with a high-fat meal.

Patients Receiving Opioid Analgesics: CONTRAVE should not be administered to patients receiving chronic opioids. Patients may be vulnerable to opioid overdose and/or precipitated opioid withdrawal.

Increase in Blood Pressure (BP) and Heart Rate (HR): CONTRAVE can cause an increase in systolic BP, diastolic BP, and/or resting HR. Monitor BP and HR especially in patients with cardiac or cerebrovascular disease and/or with controlled hypertension.

Allergic Reactions: Anaphylactoid/anaphylactic reactions and symptoms suggestive of delayed hypersensitivity have been reported in clinical trials with bupropion, as well as rare spontaneous reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock.

Hepatotoxicity: Cases of hepatitis, clinically significant liver dysfunction, and transient asymptomatic hepatic transaminase elevations have been observed with naltrexone exposure. Use of CONTRAVE should be discontinued in the event of symptoms/signs of acute hepatitis.

Activation of Mania: Prior to initiating CONTRAVE, screen patients for history of bipolar disorder and the presence of risk factors for bipolar disorder (eg, family history of bipolar disorder, suicide, or depression).

Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs, including bupropion, a component of CONTRAVE, may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.

Use of Antidiabetic Medications: Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus treated with insulin and/or insulin secretagogues (eg, sulfonylureas). Monitor blood glucose levels.

Adverse Reactions: Most common adverse reactions (≥5%) include: nausea (32.5%), constipation (19.2%), headache (17.6%), vomiting (10.7%), dizziness (9.9%), insomnia (9.2%), dry mouth (8.1%), and diarrhea (7.1%).

Drug Interactions: Increased risk of hypertensive reactions can occur when CONTRAVE is used concomitantly with MAOIs. Use caution and consider dose reduction of drugs metabolized by CYP2D6 when using with CONTRAVE. Avoid concomitant use with CYP2B6 inducers. Reduce CONTRAVE dose when taken with CYP2B6 inhibitors. Dose CONTRAVE with caution when used with drugs that lower seizure threshold. Use caution and monitor for CNS toxicity when using CONTRAVE concomitantly with dopaminergic drugs (levodopa and amantadine). CONTRAVE can cause false positive urine test results for amphetamines.

Indication
CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of:

  • 30 kg/m2 or greater (obese) or
  • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use
The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Please see accompanying Full Prescribing Information, including Medication Guide, for Contrave.

More information is also available at www.ContraveHCP.com and www.Contrave.com.

Contrave® is a trademark of Orexigen Therapeutics, Inc. registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc. All other trademarks are the property of their respective owners.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCI and bupropion HCI extended-release), which is approved in the United States and is being commercialized there by the company’s North American partner, Takeda Pharmaceuticals. In Europe, the drug has been approved under the brand name Mysimba™ (naltrexone HCI/bupropion HCI prolonged release). Orexigen’s strategy for Contrave/Mysimba is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization.

Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the companies’ current beliefs and expectations. These forward-looking statements include statements regarding: plans to vigorously enforce Contrave intellectual property rights. Inclusion of forwardlooking statements should not be regarded as a representation by either company that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the business, including, without limitation: Orexigen’s dependence on Takeda to carry out the new CV outcomes trial and the commercialization of Contrave; competition in the obesity market, particularly from existing therapies; the ability to obtain and maintain intellectual property protection for Contrave; additional analysis of the interim results of the Light study or the additional CV outcomes trial, including safety-related data, may produce negative or inconclusive results; the therapeutic and commercial value of Contrave; and other risks described in Orexigen’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and neither Takeda nor Orexigen undertake any obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in Orexigen’s Annual Report on Form 10-K filed with the Securities and Exchange Commission February 27, 2015 and its other reports, which are available from the SEC’s website (www.sec.gov) and on Orexigen’s website (www.orexigen.com) under the heading “Investor Relations.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Contact:
McDavid Stilwell
Corporate Communications and Business Development
Orexigen Therapeutics, Inc.
+1-858-875-8629
mstilwell@orexigen.com

David Walsey
BrewLife (Media Contact for Orexigen)
+1-858-617-0772
dwalsey@brewlife.com

 

SOURCE Orexigen Therapeutics, Inc.

Marketing Assistant (Intern) – Pharmatek – San Diego, CA

April 22, 2015 – 1:44 am

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Pharmatek – 22 Apr 2015 08:44:14 GMT
– View all San Diego jobs

Quality Assurance Associate, Document Control – Pharmatek – San Diego, CA

April 22, 2015 – 1:44 am

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Pharmatek – 22 Apr 2015 08:44:09 GMT
– View all San Diego jobs